IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4123
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$43M
Gary S. Jacob
We are a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. We were originally incorporated in the British Virgin Islands as a British Virgin Islands Business Company on July 4, 2007 under the BVI Business Companies Act 2004 with company number 1415559 under the name Jellon Enterprises, Inc.. Our legal and commercial name was changed to Minor Metals & Mining, Inc. on October 24, 2007, to Emerging Metals Limited on November 28, 2007, to West African Minerals Corporation on December 9, 2011, and to OKYO Pharma Corporation on January 10, 2018. On March 9, 2018, shareholders approved the cancellation of our AIM listing and migration to Guernsey. On July 3, 2018, following the approval of the Guernsey Companies Registry, we were registered under the Guernsey Companies Law under the name OKYO Pharma Limited, as a Guernsey company with limited liability, an indefinite life and company number 65220. We are domiciled in Guernsey. On July 17, 2018, our Ordinary Shares were admitted to listing on the standard segment of the Official List of the FCA and admitted to trading on the Main Market of the London Stock Exchange. We are subject to the Takeover Code. Our registered office is located at Martello Court, Admiral Park, St. Peter Port, Guernsey.
Headcount
7
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$OKYO OKYO Pharma Ltd | 35 | 28 | 20 | 50 | - | - | 76.0% | -511.9% | - | - | - | - | 0.0% | - | $43M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
OKYO Pharma Ltd (OKYO) receives a "Avoid" rating with a composite score of 34.9/100. It ranks #4123 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Direct cash return
Gary S. Jacob
Chief Executive Officer
Labor Force
7
28
16
42
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for OKYO
HQ Base
Pending Verification
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
No analyst ratings for OKYO.
View All RatingsInsufficient data for Financial Analysis
ROE proxy 76.0% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 4yr history
Interest coverage -8.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags OKYO Pharma Ltd with an Avoid rating, assigning a composite score of 34.9/100 and 1 out of 5 stars. Ranked #4123 of 7,333 stocks, OKYO falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
OKYO's quality score of 28/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 76.0% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
OKYO registers a value score of just 20/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
OKYO Pharma Ltd's investment score of 16/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -511.9% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
OKYO demonstrates moderate momentum with a score of 50/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of 0.77 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
OKYO's stability score of 42/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.77. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 51/100 for OKYO suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include micro-cap liquidity risk. With a $43M market cap (micro-cap), OKYO Pharma Ltd may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
OKYO Pharma Ltd is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4123 of 7,333 overall (44th percentile). Key comparisons include ROE of 76.0% exceeding the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While OKYO currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (16) would have the largest impact on the composite score.
ROE 3166% BELOW SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF MAR 31, 2025 (Q4 FY2024)
We rate OKYO Pharma Ltd (OKYO) as Avoid with a composite score of 34.9/100 at a current price of $1.66. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (50th percentile) and stability (42th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (16th percentile) and value (20th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
OKYO Pharma Ltd holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.9/100 places it at rank #4123 in our full 7,333-stock universe. At $43M in market capitalization, OKYO Pharma Ltd is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (50th percentile) are neutral regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for OKYO Pharma Ltd, which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $1.66, OKYO Pharma Ltd is trading at a premium to fundamental value. Our value factor score of 20/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
Valuation multiples are not available for this company, which limits our ability to assess relative pricing. We rely more heavily on factor-based valuation signals in such cases.
Returns on equity of 76.0% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
The Avoid rating (composite 34.9/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (28th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Medium uncertainty rating to OKYO Pharma Ltd. The stock presents a balanced risk profile: weak quality scores (28th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: weak quality scores (28th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 42th percentile and quality factor at the 28th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our medium uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate OKYO Pharma Ltd's capital allocation as Poor. Key concerns include weak asset returns (ROA -511.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — OKYO Pharma Ltd significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, OKYO Pharma Ltd receives a Avoid rating with a composite score of 34.9/100 (rank #4123 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on OKYO Pharma Ltd at this time. The combination of limited competitive advantages, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign OKYO Pharma Ltd a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, economic value creation, reached only 17.5/20.
The strongest moat sources are economic value creation (17.5/20) and margin superiority (10/20). ROE proxy 76.0% (sector -2.5%). GM N/A vs sector 43%, OM N/A vs sector 1%. These pillars form the core of OKYO Pharma Ltd's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect OKYO Pharma Ltd's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include returns on equity of 76.0% driving shareholder value creation. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 28th percentile.
Return metrics include ROE of 76.0% and ROA of -511.9%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of 76.0% compares to a sector median of -2.5%.
Balance sheet data is limited, restricting our assessment of financial resilience. Investors should seek additional disclosure on leverage and liquidity before forming a complete view of financial health.
Above 50MA
37.18%
Net New Highs
+51081
4:15pm: Tariff fallout Trump’s new global tariffs saw US stocks finish the day firmly in the red. The Dow Jones fell 1.7% or about 820 points to 48,804 points, the Nasdaq was down 1.1% at 22,627 points and the S&P 500 fell 1% to 6,837 points. 3:30pm: Proactive news headlines OKYO...
Analysts from Lucid Capital, H.C. Wainwright, and B. Riley Securities have all repeated ‘Buy’ ratings on OKYO Pharma Ltd (NASDAQ:OKYO), highlighting the company’s promising urcosimod program and its potential to address an unmet need in neuropathic corneal pain (NCP). The positive sentiment...
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds of about $20 million. The clinical-stage biopharmaceutical company said it intends to use the net proceeds primarily to fund the...
OKYO Pharma (OKYO) plans an underwritten public offering of ordinary shares, with a 15% over-allotment option.